InMed Pharmaceuticals Inc.. Common
$1.71 -$0.14 (-7.57%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 22
A material event was filed (Form 8-K).
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
May 19
The stock moved +135.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 19 -
Mar 30
From its Jan 30 high, the share price fell 44%.
Peak close $1.10 on Jan 30; trough close $0.62 on Mar 30. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -44% -
Mar 4
The stock moved +22.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 4
The story updates itself as events post · The wolf reports; you decide
Snapshot
About InMed Pharmaceuticals Inc.. Common
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.